Wyeth Pharmaceuticals

About Wyeth Pharmaceuticals

Wyeth is a global leader in pharmaceuticals, consumer health care products, and animal health care products.

Wyeth improves the lives of millions of people around the world with its outstanding products. And other innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines, and biotechnology, Wyeth is exploring more than 60 new therapies for medical conditions such as diabetes, breast cancer, multiple sclerosis, HIV, Alzheimer’s disease, and schizophrenia.

Wyeth has a long history of pioneering developments in pharmaceuticals and biotechnology, with leading products in the areas of women’s health care, neuroscience, musculoskeletal disorders, cardiovascular therapy, vaccines and infectious disease, hemophilia, immunology, and oncology. Wyeth is also a leader in the development of nutritionals.

More Than 60 Years in Women’s Health Care

For more than 60 years, Wyeth has been the leader in Woman’s Health with its postmenopausal hormone therapies and oral contraceptives. Wyeth is committed to developing new therapies with the potential to significantly improve the health of women worldwide. To achieve this goal, Wyeth formed the Women’s Health Research Institute® — the only institute in the pharmaceutical industry dedicated solely to research in women’s health — and currently invests more than $130 million annually in clinical research. After several years of research, Wyeth introduced new low doses of its postmenopausal hormone therapy products. Research is currently underway on several other products intended to improve the quality of women’s lives, including a low-dose continuous contraceptive, a non-hormonal therapy for the relief of menopausal hot flashes, and a new therapy for the prevention and treatment of postmenopausal osteoporosis.

Neuroscience

Wyeth’s global neuroscience efforts have produced a novel therapy for depression and for the treatment of Generalized Anxiety Disorder. Working with three discovery platforms — small molecules, vaccines, and biotechnology — Wyeth researchers continue to develop treatments targeted for a wide range of central nervous system disabilities, such as multiple sclerosis, Alzheimer’s disease, depression, anxiety, and schizophrenia.

Vaccines and Infectious Disease

Wyeth’s vaccines and infectious disease franchises share a common mission: to reduce the number of serious illnesses and deaths from bacterial and viral infections and to address the growing problem of bacterial resistance to existing treatments. In recent years, Wyeth has developed some of the most innovative vaccines in the health care arena. Our R&D focuses on producing vaccines for infants and children around the world. We are proud of the impact Wyeth has had on children’s lives, and we are dedicated to continually developing vaccines so children can have a healthier future.

Musculoskeletal

Wyeth’s musculoskeletal franchise develops important new therapies for patients with joint and bone disorders. Our products include treatments for rheumatoid arthritis that help patients lead more active lives. In addition, Wyeth has a strong presence in the osteoarthritis treatment market. In research, Wyeth scientists are investigating novel treatments for bone and tissue repair, which may impact fracture healing and post-surgical recovery.

Internal Medicine

Our broad and expanding internal medicine franchise includes cardiovascular and gastrointestinal products. Wyeth’s internal medicine researchers are exploring novel approaches to treat diabetes, heart conditions, and vascular disorders.

Hemophilia

Since the 1980s, Wyeth has been a global leader in the search for safer and more effective treatments for hemophilia A & B. As a result of this commitment, and a significant investment in recombinant DNA technology, our efforts have led to important medical advances in the treatment of these potentially debilitating diseases.

Immunology and Oncology

Wyeth’s work in immunology focuses on producing novel immunosuppressants for organ transplantation. Our efforts in oncology include chemotherapy agents for acute myeloid leukemia and a platelet growth promoter to help patients after chemotherapy. Wyeth currently has several promising oncology therapies in clinical trials, including treatments for renal cell carcinoma, breast cancer and mantle cell lymphoma.

Research & Devlopment

An outstanding, preeminent ability in research and development tops the list of Wyeth corporate strengths. Our research and development strategy is to continue to invest in innovative products, which are essential to the long-term success of health care companies. In 2005, Wyeth spent approximately $2.7 billion on research and development, with an emphasis on pharmaceutical, vaccine, and biotechnology products. This level of spending places Wyeth among the world’s leading pharmaceutical companies in terms of research and development commitment.

Wyeth Divisions

Wyeth, headquartered in Madison, New Jersey, is one of the largest research-based pharmaceutical and health care products companies in the world. Wyeth is dedicated to solving the world's most critical health problems through research and development, spending approximately $2.7 billion in overall R&D in 2005. With annual sales of nearly $18.8 billion in 2005 and products sold in more than 145 countries, Wyeth is truly a global health care leader.

Wyeth Pharmaceuticals is comprised of R&D, prescription products, vaccines, biopharmaceuticals, and nutritionals.

Products under development include new treatments for cancers including hematologic and solid organ malignancies, inflammatory diseases including rheumatoid arthritis and asthma, infectious diseases and preventative vaccines, cardiovascular and metabolic diseases, diseases of the central nervous system, and treatments in Women’s health including osteoporosis and vasomotor symptoms of menopause.

Wyeth Pharmaceuticals

At Wyeth Pharmaceuticals, there is a vision of leading the way to a healthier world. Wyeth Pharmaceuticals are committed our to achieving this vision by making quality, integrity, and excellence the hallmarks of their business. Through recruitment, development, and motivation of the best people, Wyeth are continually growing and improving their business. Wyeth Pharmaceuticals lead in innovation by linking pharmaceutical, biotechnology, and vaccine technologies.

Headquartered in Collegeville, Pennsylvania, U.S.A., Wyeth Pharmaceuticals has global operations consisting of 37 manufacturing facilities in 17 countries and markets products in over 60 nations.

Wyeth Pharmaceuticals are committed to excellence - in the results we achieve and in how we achieve them. Wyeth pride themselves on quality manufacturing; responsible sales, marketing, and licensing alliances; commitment to educational programs and initiatives; and service to health care professionals and patients.

Wyeth Pharmaceuticals employ approximately 44,000 people worldwide - each one committed to improving the health of people around the world. The diverse and talented people who work at Wyeth bring to the company a full range of talent in research, marketing, sales, and manufacturing. It is the Wyeth employees who keep Wyeth on the cutting edge of innovative discoveries and superior customer service.

Latest Wyeth Pharmaceutical news

Wyeth further information:
www.wyeth.com | www.wyeth.co.uk | Wyeth news

Page last updated: 05/06/08

Pharmaceutical product information and articles
Get the latest Pharmaceutical drug reviews, reports & pharmaceutical intelligence


Contact \| Suggest Pharmaceutical Resource	Copyright © Net Media Marketing. All rights reserved.

Pharmaceutical jobs, Medical / Pharmaceutical sales jobs, Pharmaceutical Company, Pharmaceutical, Pharmajobs, Pharma jobs, Pharmaceutical sales Pharmaceutical jobs, Healthcare sales, Laboratory sales, Veterinary sales jobs, Dental sales jobs, Trainee sales jobs, Nurse Advisor jobs, Sales Management, Pharma Marketing, Senior Management, Regulatory & Clinical & Scientific sales jobs